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Purpose: Glutathione S-transferases (GSTs) are a family of enzymes that inactivate xenobiotics and endogenous end
products formed as secondary metabolites during oxidative stress. In humans, GSTT1 and GSTM1 deletion genotypes
(T0M1, T1M0, and T0M0) are associated with a variety of pathologic processes including certain ophthalmologic diseases.
Methods: We compared the prevalence of GSTT1 and GSTM1 deletion genotypes, which were determined by multiplex
polymerase chain reaction, in 107 Arab patients with glaucoma (49 with primary open-angle glaucoma, 29 with
pseudoexfoliation glaucoma, and 29 with primary angle-closure glaucoma) to 120 age, sex, and ethnically matched
controls.
Results: All three GST polymorphisms were significantly more common in the entire glaucoma group (p<0.0167) than
in controls. However, when patients were stratified by glaucoma type, the deletion genotype, T0M0, was not particularly
associated with any type of glaucoma tested. The T1MO genotype was more common among patients with each type of
glaucoma than among controls whereas T0M1 genotype was more common among pseudoexfoliation glaucoma (PEG)
and primary open-angle glaucoma (POAG) patients than controls.
Conclusions: The overall results indicate a possible variable association between various GSTT1 and GSTM1 genotypes
and glaucoma in this population. Decreased GST function might interfere with the metabolism of oxidative intermediates
and exacerbate the direct or indirect damaging effects of oxidative stress on the optic nerve. It is possible that these GST
polymorphisms may be risk factors for glaucoma.
Glaucoma is the most common optic neuropathic process
affecting humans and the second most common cause of
blindness worldwide [1]. It is a complex, heterogeneous
disease with a multifactorial etiology including mechanical
damage due to increased intraocular pressure (IOP), variable
susceptibility of the optic nerve [2], mutations in specific
nuclear genes [3], changes in the mitochondrial genome [4],
and toxic effects and oxidative damage caused by reactive
oxygen species (ROS) [3,5,6].
The glutathione S-transferases (GSTs) are a family of
enzymes consisting of numerous cytosolic, mitochondrial,
and microsomal proteins capable of multiple reactions with
endogenous and xenobiotic substrates. They catalyze the
conjugation of reduced glutathione to electrophilic centers via
the sulfhydryl group on a wide variety of substrates [7]. GSTs
bind toxins, function as transport proteins, detoxify
endogenous compounds such as peroxidized lipids [8], and
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inactivate endogenous end products formed as secondary
metabolites during oxidative stress.
In humans, GST enzymes are divided into five classes
− alpha (A), mu (M), pi (P), theta (T) and zeta (Z) − with each
class encompassing several genes and isoenzymes. Previous
studies of allelic variants in these classes have identified two
major polymorphisms of the GSTT1 and GSTM1 genes caused
by a deletion in each gene. These deletions result in the virtual
absence of enzyme activity, particularly in individuals with
deletions in both genes (null genotype). The null genotype
(T0M0) has been associated with altered risk of a variety of
pathologies including cancer, cardiovascular disease, and
respiratory disease [9-11]. GST polymorphisms have also
been associated with ophthalmologic problems such as
cataract [12] and senile macular degeneration [13].
We recently reported evidence of mitochondrial
abnormalities in patients with primary open-angle glaucoma
(POAG), implying that an oxidative stress mechanism might
contribute to the pathogenesis of POAG [4]. In fact, several
studies have found GST polymorphisms to be risk factors in
POAG [14-17]. Because of the role of GSTs in inactivating
endogenous end products formed as secondary metabolites
during oxidative stress, we decided to compare the
distribution of GSTM1 and GSTT1 polymorphisms in Saudi
patients with POAG, pseudoexfoliation glaucoma (PEG), and
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425primary angle-closure glaucoma (PACG) to the distribution
in matching healthy controls.
METHODS
Patients and controls: A total of 107 glaucoma patients (49
with POAG, 29 with PEG, and 29 with PACG) were enrolled
in this study. The inclusion and exclusion criteria for each type
of glaucoma were detailed elsewhere [4,18,19]. All patients
were Saudi Arabs selected from the Glaucoma Clinic at King
Khaled Eye Specialist Hospital (KKESH) after an
examination by a glaucoma specialist (J.M.) and informed
consent approved by the KKESH IRB. Records were
reviewed, a general medical history was taken, and complete
ophthalmologic examinations were performed. Patients had
either Goldmann manual kinetic perimetry (Haag Streit AG,
Koeniz-Berne, Switzerland), Humphrey automated white on
white stimulus static perimetry (Humphrey Field Analyzer II,
Humphrey Systems, Dublin, CA), or both. Optical coherence
tomography was performed with the OCT3 Unit by
Humphrey Systems (San Leandro, CA) on some patients.
Fundus photos were obtained using a Zeiss FF 450 system and
conventional film. This research followed the tenets of the
Declaration of Helsinki. Family members were not evaluated
clinically or genetically.
Control subjects were blood donors at the King Faisal
Specialist Hospital and Research Centre who represented the
spectrum of Saudi Arabs and who reported no symptomatic,
metabolic, genetic, or ocular disorder on an extensive
questionnaire about family history, past medical problems,
and current health.
Sample collection and DNA extraction: Peripheral blood
(5 ml) was collected in EDTA tubes from all participating
individuals after obtaining their written consent. DNA
extraction was performed using the PURGENE DNA
isolation kit from Gentra Systems (Minneapolis, MN), and the
DNA was stored in aliquots at –20 °C until required.
Analysis of GSTM1 and GSTT1 polymorphisms: This was
performed by multiplex polymerase chain reaction (PCR)
amplification using the following primers: GSTT1 forward
primer 5`-TTC CTT ACT GGT CCT CAC ATC TC −3`;
GSTT1 reverse primer 5`-TCA CCG GAT CAT GGC CAG
CA −3`; GSTM1 forward primer 5`- GAA CTC CCT GAA
AAG CTA AAG C −3`; and GSTM1 reverse primer 5`- GTT
GGG CTC AAA TAT ACG GTG G −3`. Each 25 µl PCR
reaction contained 2.5 µl of 10X reaction buffer with MgCl2
(Amersham Pharmacia Biotech, Piscataway, NJ), 10 ρmol of
each primer, 100 ρmol/µl each of deoxynucleoside
triphosphates (deoxyATP, deoxyguanosine triphosphate,
deoxycytidine triphosphate, and deoxythymidine
triphosphate; Perkin-Elmer Corporation, Foster City, CA) in
Tris-HCl buffer, 1 unit of HotStar Taq DNA polymerase
(Amersham Pharmacia Biotech, Piscataway, NJ), and 100 ng
genomic DNA template at annealing temperature of 58 °C for
40 cycles. The PCR products were visualized on a 2% agarose
gel electrophoresis at 100 V for 50 min. Two bands of 459 bp
for GSTT1 and 209 bp for GSTM1 were obtained for the T1M1
genotype. The T1M0 genotype showed one band of 459 bp,
and the T0M1 genotype showed a band of 209 bp. For the
T0M0 genotype (homozygous absence or deletion genotype
is designated as null genotype), no bands were obtained and
thus the use of β-globin internal positive control was necessary
to distinguish the null genotype from aborted PCR reactions.
Statistical analysis: Genotype frequencies, sex distribution,
and smoking history were compared among the different
glaucoma groups and the controls by the chi square test. The
mean age comparison between patients and controls was
analyzed by t-test. A two-tailed p value of less than 0.05 was
considered statistically significant, and odds ratio with 95%
confidence intervals were reported. The Bonferroni correction
was used to adjust the significance level of a statistical test to
protect against Type I errors when multiple comparisons are
being made. All analyses were performed using SPSS v.13
statistical analysis software (SPSS Inc., Chicago, IL).
RESULTS
Most of these patients were included in previous reports of
nuclear and mitochondrial genetics in patients with glaucoma
[4,18,19]. The control group consisted of 120 individuals (78
males and 42 females, mean age 60.5 ± 9.1 years). All patients
and control subjects were of Saudi Arabian origin.
Table 1 shows demographic data for glaucoma patients
and controls. Patients and controls were not significantly
different with respect to sex, age, and smoking status
(p>0.0167); therefore, these variables were not evaluated
further.
Table 2 shows the GST genotype distribution among all
glaucoma patients and controls. The frequency of all
genotypes investigated was significantly greater among
glaucoma patients than controls.
We also examined GST genotype distribution in all three
variants of glaucoma. Table 3 shows that the frequency of the
T1M0 and T0M1 genotypes was significantly greater in
POAG patients than in controls (p=0.00001) while the
frequency of the T0M0 null genotype was not significant
(p=0.06). Table 4 shows that all deletion GST genotype
frequencies were greater in PEG patients than in controls,
except for the T0M0 null genotype, which fell slightly short
of significance (p=0.021). Table 5 shows that the frequency
of the T1M0 genotypes was significantly greater in PACG
patients than in controls (p=0.0002) whereas T0M0 and T0M1
were not significant.
DISCUSSION
Glaucoma patients in this study met strict criteria for POAG,
PEG, and PACG, which have been described previously [4,
18,19]. Controls in this study were well matched to patients
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426for age, sex, ethnicity, and smoking status. The T1M0 and the
T0M1  genotypes  were  significantly  more  common  in  the
entire glaucoma group and were almost all more common in
each individual variant of glaucoma as well. The full deletion
(T0M0 null genotype) was almost not associated with any
particular type of glaucoma. We believe that this is the first
study  to  quantify  the  prevalence  of  these  polymorphisms
among Arab patients with various types of glaucoma.
Our  results  are  in  concordance  with  previous  studies
associating GSTT1 or GSTM1 gene deletions with POAG in
Turkish [14,17], Estonian [15], and Italian [16] populations,
although one study reported no association between these
genotypes and POAG in a Swedish population [20]. The lack
of association found in the Swedish population may represent
a population specific effect, e.g., caused by differences in
genetic background between various world populations. The
frequency of these genotypes among controls reported here
was similar to that reported previously in Saudi Arabs [9] but
moderately different from frequencies reported in a Turkish
population [17]. These differences may reflect varying ethnic
and genetic backgrounds of the populations studied. We were
unable to determine whether these polymorphisms were in
Hardy–Weinberg  equilibrium  because  heterozygous
individuals could not be distinguished from homozygous wild
type and because the high consanguinity rate in the Saudi
population  (>65%)  means  that  the  random  mating
requirement is not satisfied [21]. We did not quantify the
interaction between GST genotypes, smoking status, and the
development of glaucoma, since only five of our glaucoma
patients (4.7%) were smokers.
Glaucoma  is  a  heterogeneous  disease  with  several
important variants that differ at least partially in the apparent
TABLE 1. DEMOGRAPHIC DATA OF THE STUDY GROUPS.
Study group Glaucoma group Control group
Number of subjects 107 120
Sex
Male, n (%) 68 (63.6%) 78 (65.0%)
Female, n (%) 39 (36.4%) 42 (35.0%)
Age (years)
Mean (SD) 60.6 (8.8) 60.5 (9.1)
Smoking
Yes, n (%) 5 (4.7%) 7 (5.8%)
No, n (%) 95 (88.8%) 113 (94.2%)
Unknown, n (%) 7 (6.5%) 0
Patients and controls were not significantly different with respect to sex, age and smoking status (p>0.0167).
TABLE 2. GLUTATHIONE S-TRANSFERASE GENOTYPES AND THE RISK OF DEVELOPING GLAUCOMA.
GST genotypes Controls (n=120) Glaucoma patients
(n=107)
Odds ratio 95% Confidence
interval
p-Value
T1M1 102 (85%) 43 (40.2%) Reference - -
T0M0 3 (2.5%) 9 (8.4%) 7.12 1.65 – 35.0 0.002
T1M0 10 (8.3%) 38 (35.5%) 9.01 3.89 – 21.3 0.00001
T0M1 5 (4.2%) 17 (15.9%) 8.07 2.58 – 26.9 0.00001
The frequency of all deletion genotypes investigated was significantly greater among glaucoma patients than controls (after
Bonferroni correction, p-value < 0.0167 was considered statistically significant).
TABLE 3. GLUTATHIONE S-TRANSFERASE GENOTYPES AND THE RISK OF DEVELOPING PRIMARY OPEN-ANGLE GLAUCOMA.
GST genotypes Controls (n=120) POAG patients
(n=49)
Odds ratio 95% Confidence
interval
p-Value
T1M1 102 (85%) 18(36.7%) Reference - -
T0M0 3 (2.5%) 3 (6.2%) 5.67 0.83 – 39.2 0.06
T1M0 10 (8.3%) 18 (36.7%) 10.2 3.72 – 28.6 0.00001
T0M1 5 (4.2%) 10 (20.4%) 11.3 3.07 – 44.0 0.00001
The frequency of the T1M0 and T0M1 genotypes was significantly greater in POAG patients than controls (p=0.00001), while
the frequency of the T0M0 null genotype which was not significant (p=0.06). After Bonferroni correction, p-value < 0.0167
was considered statistically significant.
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427mechanisms  of  optic  nerve  injury.  For  example,  POAG
typically has lower IOP and no obvious ocular changes (in
contrast  to  PEG  or  PACG)  and  is  suspected  of  being
associated with molecular and biochemical abnormalities [2].
Optic  nerve  injury  in  PEG  is  a  component  of
pseudoexfoliation  syndrome,  a  systemic  condition  [22,23]
that may include stroke and myocardial infarction [24,25], and
is  frequently  associated  with  severe  chronic  open-angle
glaucoma and cataract [26]. A recent genome-wide screen of
Icelandic and Swedish populations detected an association of
PEG  with  two  nonsynonymous  single  nucleotide
polymorphisms (SNPs) in exon 1 of the LOXL1 gene [27].
Unfortunately, samples were no longer available for us to test
this association among our PEG patients.
PACG  has  been  attributed  primarily  to  elevated  IOP
caused by anatomic changes in the anterior [28] and posterior
[29] globe. However, in each variant, ocular phenomena must
interact with the posterior globe to cause optic nerve injury
[26,29,30], and recent evidence supports the hypothesis that
ROS and oxidative stress may play a contributing role in
glaucomatous  optic  nerve  injury  at  several  levels  [31].
Oxidative  stress  may  be  directly  involved  in  optic  nerve
neuronal  cell  death  [32].  In  addition,  human  trabecular
meshwork (TM) possesses abundant antioxidant activity, and
ROS  compromise  TM  integrity  [16,33].  Oxidative  DNA
damage is increased in TM in POAG [34], which might induce
degenerative changes favoring increased IOP [34]. Therefore,
oxidative stress early in the development and/or throughout
life might precipitate both metabolic and anatomic sequelae
that increase the risk of optic nerve damage in glaucoma. This
may be true even in glaucoma variants that seem primarily
anatomic in the mechanism of optic nerve injury such as
PACG.
GST  enzymes  inactivate  endogenous  unsaturated
aldehydes, quinines, epoxides, and hydroperoxides and also
protect blood vessels from the effects of endogenous oxidants
formed  as  secondary  metabolites  during  oxidative  stress
[35]. It is plausible that decreased GST enzyme activity might
contribute to inadequate inactivation of these metabolites,
exacerbating oxidative stress and increasing the chance of
glaucomatous optic nerve injury directly (e.g., in the optic
nerve) or remotely (e.g., in the TM and possibly elsewhere in
the globe) or both. These effects might be independent of the
specific ocular characteristics of the glaucoma syndrome. In
fact, the results presented here imply that defects in GST
activity  may  well  be  risk  factors  for  developing  all  three
variants of glaucoma evaluated. The exact mechanisms by
which this occurs are not clear, which is not surprising given
that the exact mechanisms of GST activity have yet to be
elucidated [35].
In  conclusion,  this  study  indicates  an  association  of
GSTT1 and GSTM1 polymorphisms to a variable degree with
three types of glaucoma. Further investigations are warranted
into  the  precise  mechanism  by  which  these  genetic
polymorphisms may influence the development of glaucoma.
TABLE 4. GLUTATHIONE S-TRANSFERASE GENOTYPES AND THE RISK OF DEVELOPING PSEUDOEXFOLIATION GLAUCOMA.
GST genotypes Controls (n=120) PEG patients (n=29) Odds ratio 95% Confidence
interval
p-Value
T1M1 102 (85%) 11 (37.9%) reference - -
T0M0 3 (2.5%) 3 (10.3%) 9.27 1.28 – 68.5 0.021
T1M0 10 (8.3%) 10 (34.5%) 9.27 2.81 – 31.3 0.00001
T0M1 5 (4.2%) 5 (17.3%) 9.27 1.93 – 45.8 0.003
All deletion GST genotype frequencies were greater in PEG patients than controls, except for the T0M0 null genotype, which
fell  slightly  short  of  significance  (p=0.021).  After  Bonferroni  correction,  p-value  <  0.0167  was  considered  statistically
significant.
TABLE 5. GLUTATHIONE S-TRANSFERASE GENOTYPES AND THE RISK OF DEVELOPING PRIMARY ANGLE-CLOSURE.
GST genotypes Controls (n=120) PACG patients
(n=29)
Odds ratio 95% Confidence
interval
p-Value
T1M1 102 (85%) 14 (48.3%) Reference - -
T0M0 3 (2.5%) 3 (10.3%) 7.29 1.04 – 51.9 0.034
T1M0 10 (8.3%) 10 (34.5%) 7.29 2.30 – 23.5 0.0002
T0M1 5 (4.2%) 2 (6.9%) 2.91 0.35 – 19.7 0.225
The frequency of the T1M0 genotype was significantly greater in PACG patients than in controls (p=0.0002), whereas the
prevalence of T0M0 and T0M1 genotypes were not statistically different from controls. After Bonferroni correction, p-value <
0.0167 was considered statistically significant.
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